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Background: Patients with aneurysmal subarachnoid hemorrhage (aSAH) are common in intensive care units (ICU).
In patients with aSAH, sedation is used as a neuroprotective measure in order to secure adequate cerebral
perfusion pressure (CPP). Compared with the use of an endotracheal tube, a tracheotomy has the advantage of
securing the airway at a much lower level of distress, and aSAH patients can often be awakened more rapidly. Little
is known about the impact of tracheotomy on the consumption of sedative/analgesic and vasoactive drugs and
the maintenance of CPP within defined limits in aSAH patients.
Methods: We conducted an observational study of aSAH patients who underwent percutaneous tracheotomy. A
prospective registry of patient data was supplemented with retrospective retrievals from medical records. Sedative,
analgesic and vasoactive drug doses were registered for 3 days prior to and after percutaneous tracheotomy,
respectively. Blood pressure, CPP, and the mode of mechanical ventilation were registered 24 h prior to and after
tracheotomy.
Results: Between January 2001 and June 2009, 902 aSAH patients were admitted to our hospital; 74 (8%) were deeply
comatose/dying upon arrival. The ruptured aneurysm was repaired in 828 patients (surgical repair 50%) and percutaneous
tracheotomy was performed 182 times in 178 patients (59 men and 119 women). This subpopulation (178 of 828
patients) was significantly older (56 vs. 53 years) and presented with a more severe Hunt & Hess grade (p < 0.001).
Percutaneous tracheotomy caused a marked decline in mean daily consumption of the analgesics/sedatives fentanyl,
midazolam, and propofol, as well as the vasoactive drugs noradrenaline and dopamine. These declines were statistically
and clinically significant. The mean CPP was 76 mmHg (SD 8.6) the day before and 79 mmHg (SD 9.6) 24 h after
percutaneous tracheotomy. After percutaneous tracheotomy, mechanical ventilatory support could be reduced to a
patient-controlled ventilatory support mode in a significant number of patients (p < 0.001).
Conclusions: Percutaneous tracheotomy in aSAH patients is a swift procedure with low risk that is associated with a
significant decline in the consumption of sedative/analgesic and vasoactive drugs while clinical surveillance parameters
remain stable or improve.
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Patients with aneurysmal subarachnoid hemorrhage
(aSAH) are common in neurocritical care departments.
In conjunction with sedation and continuous monitoring
in the intensive care unit (ICU), early aneurysm repair
and adequate management of acute hydrocephalus are
crucial parts of initial treatment. Local management
guidelines include sedation protocols, regulation of ar-
terial blood pressure (ABP), and maintenance of intra-
cranial pressure (ICP) below the defined critical
threshold. Adequate cerebral perfusion pressure (CPP),
which is defined by the difference between mean ABP
and mean ICP, is a cornerstone of optimal management.
Following aneurysm repair, our departmental guidelines
consider CPP >70 mmHg to be the goal for most aSAH
patients. In the presence of severe cerebral vasospasm,
the CPP threshold can be raised to >90 mmHg.
Sedation with opioids, propofol, or benzodiazepines
invariably lowers mean ABP, and the administration of
vasoactive drugs may be required to maintain the target
CPP. Depending on the severity of brain injury, the pa-
tient’s co-morbidities, and day-to-day assessment of the
optimal treatment strategy, the patient may need secure
airway access and ventilatory support. While most ICU
patients need sedation and pain relief, sedation is also
used as a neuroprotective measure in patients with
aSAH. When sedated, the brain consumes less oxygen.
Furthermore, deeper sedation represents one aspect of
preventing or treating increases in ICP.
When the patient regains consciousness he or she may
experience discomfort related to the endotracheal tube.
When such a stress response is induced, ICP will in-
crease. Frequent coughing may also increase ICP, and
can cause unintended excessive cerebrospinal fluid
(CSF) drainage through external CSF drains. These situ-
ations may necessitate increased sedation. Compared
with the use of an endotracheal tube, a tracheotomy has
the advantage of securing the airway at a much lower
level of distress, and the aSAH patient can often be
awakened more rapidly. Little is known about the impact
of a tracheotomy on the consumption of sedative/anal-
gesic and vasoactive drugs and the maintenance of CPP
within the defined limits. In order to answer these ques-
tions, we performed the present observational study on
aSAH patients that were managed using a percutaneous
tracheotomy (PT).
Methods
The Regional Committee for Medical and Health Re-
search Ethics for South-East Norway approved the
protocol of this study, and the study was exempted from
the regulations of informed consent by the Norwegian
Directorate of Health. The presentation of the study is
prepared according to the STROBE guidelines [1].All aSAH patients admitted to our hospital between Janu-
ary 2001 and June 2009 were acquired from a prospective
registry. Some of these patients represent a sub-group of a
previously published analysis in a general ICU population
(N = 1000) [2]. The total patient population in our ICU is a
mixture of medical and surgical intensive care cases, and
the approximate mean number of annual ventilator days
during this time period was 4,000. Aneurysmal SAH was
the most frequent diagnosis, followed by heart failure, non-
aneurysmal intracerebral hemorrhage, and intracerebral or
intracerebellar infarction.
Anesthesiologists direct the ICU, and also performed
all PTs. The decision of whether and when to establish a
PT was based on clinical grounds by the neurosurgeon
and the anesthesiologist in charge. Reduced sedation and
wake-up were considered once the aneurysm was se-
cured and the patient was stable and well within defined
monitoring thresholds. Wake-up and extubation of the
orotracheal tube as soon as feasible was one of the pri-
mary treatment goals. However, elevated ICP, serious
cerebral vasospasm, and/or respiratory problems were
indicative of a prolonged time interval before it would
be possible to awaken the patient, and hence prompted
consideration of tracheotomy. Severely impaired lung
function with inspired oxygen fraction >60% or positive
end expiratory pressure >10 cmH2O, led to postpone-
ment of PT until lung function improved, as would any
cerebral instability, in particular increased ICP. The PT
was performed by an experienced consultant or by a
registrar supervised by a senior consultant in the ICU
using a well established technique described elsewhere
[3]. A third anesthesiologist secured the airway using
direct laryngoscopy and fiber-optic bronchoscopy. The
staff reported all PTs to the principal investigator, who
consecutively recorded patient demographic data, pri-
mary diagnosis, the number of days on mechanical ven-
tilation, duration of the procedure, and complications
during the procedure and the following 48 h. Details re-
garding the aSAH patients were acquired from another
registry and included demographic data, Hunt and Hess
grade [4] prior to aneurysm repair or prior to sedation,
angiographic classification, and mode of aneurysm re-
pair. The sedative/analgesic and vasoactive drug doses
were registered during the final 3 days prior to and the
first 3 days after PT. Mean ABP, mean ICP, CPP, and the
mode of mechanical ventilation were registered the day
before and 24 h after the PT. Mode of mechanical ventila-
tion was graded as 1 = spontaneous ventilatory support,
2 = partly controlled ventilation and patient-triggered
ventilation, and 3 = controlled ventilation without patient
triggering. The day of PT intervention was excluded from
the analyses because the procedure requires variable
amounts of analgesics and anesthetics. Each patient’s
height and weight were measured, reported by relatives, or
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body mass index (BMI) was calculated based on these
values. We used 90-day mortality rates for our analysis.
The date of demise originating from the National Popu-
lation Registry-Norway was collected from the patients’
electronic records.
Statistical analysis
Demographic data, continuous numerical variables, and
proportions are presented as mean and standard devi-
ation or standard error, as median and range, or as inter-
quartile range, where appropriate. Proportions were
analyzed using the Chi-square test or Fisher’s exact test
(specified in the results when relevant). The before- and
after-effects of the mode of mechanical ventilation were
tested statistically using the test for related marginal
homogeneity in SPSS® version 21 for Windows (Statis-
tical Packages for the Social Sciences), Chicago, IL. Sex
differences were tested statistically with an independent
sample t-test if normally distributed, or a Mann–Whitney
U test. Risk factor analyses were performed using a linear
regression model or Chi-square test. The statistical tests
were performed with SPSS® version 18 for Windows,
Chicago, IL. Figures were created with SigmaPlot® ver-
sion 12.5 for Windows (SigmaPlot®, Windows, Systat
Software, San Jose, CA).
Results
A total of 902 patients with aSAH were admitted to the
hospital during the 8.5-year study period. Seventy-four
(8%) of these patients did not have their aneurysm
secured because they were deeply comatose/dying upon
arrival. Among the 828 patients that underwent aneurysm
repair, PT was performed 182 times in 178 patients
(59 men and 119 women, Table 1). Three patients
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PT; percutaneous tracheotomy, HH; clinical grade before securing of the aneurysm/
and poor grade (HH grade 4 and 5), MCA; Middle cerebral artery, ACA; Anterior Cerebr
BA; basilar artery, sign; statistical significance.third PT. The mean (SD) duration of mechanical ventila-
tion before PT was 5.3 (2.8) days, and the mean (SD)
interval from ictus to PT was 5.8 (4.2) days.
The mean PT procedural time was 12.5 min (SD = 8.6,
median 10 min, range 1–50 min). There was no
procedure-related mortality. Difficulties during insertion of
cannula, guide wire, or tracheal tube were registered in 19
patients, and minor bleeding was registered in 11 patients.
One procedure was complicated by a short loss of airway
control, one patient had perioperative hypoxia in spite of
airway control, and one patient developed pneumothorax.
The distributions of sex, age, intervention, preoperative
Hunt & Hess grade, and location of the ruptured
aneurysm in patients with and without PT are shown in
Table 1. The PT patients were older (mean age
56 years vs. 53 years, p = 0.005) and presented with
more severe Hunt & Hess grade (p < 0.001). They
were in poorer clinical condition prior to aneurysm
repair; more than 70% presented with Hunt & Hess grade
4 or 5, compared with 19% of the non-PT patient popula-
tion. Patient characteristics among men and women in the
PT group are displayed in Table 2. Severity on admission
was higher in the female population as 76% had Hunt &
Hess grade 4 or 5 compared to 70% in men (Table 1). In
the PT population, surgical aneurysm repair was per-
formed in 50% of patients (Table 1). The 90-day mortality
rate was 25% (95% CI 18.3 – 31.1).
Mean daily consumption of fentanyl, midazolam,
and propofol tended to increase during the 3 days
immediately before PT, but decreased significantly
during the 3 days immediately after PT (Table 3,
Figure 1). Likewise, mean daily consumption of noradren-
aline and dopamine dropped significantly after PT and con-
tinued to decline during the 3 days after PT (Figure 2).
Mean CPP was 76 mmHg (SD 8.6) the day before and




56 (21 – 78) p = 0.005
50.0
1 - 3 4 - 5
27.0 73.0 p < 0.001
BA MCA ACA ICA BA
6.8 21.3 37.1 8.5 6.2 NS
sedation according to Hunt and Hess [4] presented as good grade (HH grade 1-3)
al Aretery, including anterior communicating artery, ICA; Internal carotid artery,
Table 2 Percutaneous tracheotomy patient characteristics
Male Female significance
Age (years) 53 (33–77) 59 (21–78) NS
Height (cm) 181 (6.2) 167 (4.6) NS
Weight (kg) 87 (15)(60–128) 69 (11)(51–115) NS
BMI (kg/m2) 27 (4) 24 (3) NS
Baseline HH grade 4 (IQR 2) 4 (IQR 1.25) NS
Demographic data of patients presented as mean (standard deviation), median
and range, or inter quartile range (IQR). BMI; body mass index, HH; Hunt Hess
grade [4].
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(controlled ventilation) (interquartile range 2–3) before
PT and 2 (spontaneous ventilation) (interquartile range
1–3) after PT (p < 0.001; Figure 3).
Discussion
The main findings of the present study were that per-
cutaneous tracheotomy (PT) can be performed safely
in aSAH patients and that consumption of analgesics,
sedatives, and vasoactive drugs became markedly re-
duced after PT.
Percutaneous tracheotomy
During the past decade, PT has become a routine method
in the ICU. Randomized trials have documented a lower in-
cidence of bleeding and infections compared with open
surgical tracheotomy [5-8]. PT is cost-effective [9] and can
be performed in a shorter procedure time than surgical
tracheotomy [8], with minimal risk of increasing ICP [10].
Our present finding of a median procedural time of 10 min
and few adverse events corroborates these reports. Regard-
ing cost-effectiveness, the present study did not investigate
outcome or total hospital time. Nevertheless, the drastic re-
duction in analgesics/sedatives and vasoactive drugs ob-
served after PT may counterbalance some or all of the cost
of performing PT.
Timing of the tracheotomy in ventilated patients has
been the focus of some randomized trials [11]. One ran-
domized controlled trial recently reported similar com-
plication rates and patient outcomes in early versus late
PT [12]. Because the benefits of timely tracheotomy in
the patient population with aSAH may differ from those
in the general ICU population, it would have been of
interest to perform controlled comparisons in aSAHTable 3 Administration of sedative drugs before and
after PT
Before PT After PT sign
Fentanyl (mg/day) 3.5 (2.7) 2.4 (3.9) p = 0.001
Midazolam (mg/day) 277 (315) 168 (289) p < 0.001
Propofol (mg/day) 1618 (1687) 842 (1475) p < 0.001
Fentanyl, midazolam, and propofol presented as mean (standard deviation) of
the three last days before PT and the three days after PT.patients or to analyze this subgroup of patients in the
large randomized controlled trials that have already been
performed. However, because even the biggest random-
ized controlled trial addressing the timing of tracheot-
omy included only a small number of patients with
intracranial pathology, a new, prospective, randomized
study in this patient population will be necessary.
Vasoactive drugs
Aneurysmal SAH is a life-threatening event, associated with
a mortality rate as high as 75% in poor grade patients
[13,14]. Some of this mortality can be attributed to delayed
cerebral ischemia. Hence, optimizing the CPP (usually
>70 mmHg) is a central part of the treatment protocol, and
sedated patients most often require vasoactive drugs to ob-
tain the prescribed CPP. The safety of vasoactive drugs re-
garding the cerebral vasculature is not well documented;
therefore, titrating vasoactive drug doses as low as possible
is mandatory. This is particularly important regarding the
most feared complication of aSAH: cerebral vasospasm.
One might raise concerns that the use of vasoactive drugs
could exacerbate and/or prolong cerebral vasospasm.
However, little is known about the effect of vasoactive
drugs on the human intracranial vasculature. One ran-
domized study conducted by Rondeau et al. has com-
pared the combination of noradrenaline and dobutamine
with noradrenaline alone [15]. They hypothesized that the
dobutamine-induced increase in cardiac output might re-
duce the incidence of intracranial vasospasm, but failed to
show any difference. Experimental data in rabbits indicate
that noradrenaline-induced hypertension may increase the
diameter and flow in vasospastic intracranial vessels [16].
Our clinical experience supports that noradrenaline is
safe, although the benefit of high-dose noradrenaline is
controversial.
Phenylephrine represents an alternative to noradren-
aline and is commonly used to increase blood pressure
to target CPP in neurointensive care [17]. Dopamine is
less used [18], but may be indicated if monotherapy with
noradrenaline causes bradycardia. Adrenaline should not
be used, as it may cause vasospasm [19]. Regardless, the
rate of possible vasoactive drug-induced adverse events
will be lower if the target CPP can be maintained at
lower levels of vasoactive drugs. The present study dem-
onstrates that PT had a profound impact on vasoactive
drug levels, with a marked and ongoing drop in drug
usage during the first 3 days after PT.
Because cerebral vasospasm may lead to delayed cere-
bral ischemia and is a major contributor to poor out-
come [20], prophylaxis and treatment of vasospasm are
imperative. The neurointensivist will often face the di-
lemma between optimizing the CPP and minimizing the
vasoactive and sedative/analgesic drug doses, especially
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Figure 1 Daily consumption of sedative/analgesic drugs. Daily consumption of fentanyl (a), midazolam (b), and propofol (c) (mg/24 h)
presented as mean (SEM) during the 3 days before and the 3 days after tracheotomy.
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Figure 2 Daily consumption of vasoactive drugs. Daily consumption of dopamine and noradrenaline (mg/24 h) presented as mean (SEM)
during the 3 days before and the 3 days after tracheotomy.
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Figure 3 Mechanical ventilator mode 24 h before and after tracheotomy. The modes of mechanical ventilation were graded as follows:
1 = spontaneous ventilatory support mode; 2 = partly controlled ventilation and patient-triggered ventilation; and 3 = controlled ventilation
without patient triggering. Data were registered 24 h before (black columns) and 24 h after (grey columns) tracheotomy.
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after PT, the CPP was easier to control; the mean ICP
remained low even when the patient was less sedated.
This was likely caused by the reduced level of stress as-
sociated with a PT versus an orotracheal tube.Sedative/analgesic drugs
A retrospective analysis of 312 patients in a general ICU
population documented that administration of sedatives
decreased after PT [21], while the observed decrease
prior to and after tracheotomy in a 48-h perspective in a
study of 1,780 patients did not reach statistical significance
[22]. Our study solely comprises aSAH patients, and the
fact that these patients require ICP control may have had
an impact on our findings. Many aSAH patients experience
severely reduced consciousness after the ictus, and pro-
longed mechanical ventilation is necessary. Sedation con-
tinues during invasive ventilatory support, as guided by
surveillance thresholds for ICP, CPP, blood oxygenation,
and other parameters. We observed a statistically and clin-
ically significant decrease in the consumption of sedative/
analgesic drugs after PT. The doses of fentanyl and midazo-
lam were larger than in a general ICU population [21], and
the decrease in drug doses was greater than expected and
could not be attributed to the expected natural course of
disease. In contrast, the use of sedatives/analgesics was in-
creasing during the 3 days prior to PT. At our ICU, the
amount of sedatives used in aSAH patients is usually re-
duced as soon as is feasible; however, if such a reduction
leads to ICP and/or CPP beyond the desired thresholds,
sedation is again increased. Hence, tracheotomized patients
experience less discomfort when their level of conscious-
ness is increasing, compared with patients having an
orotracheal tube. Both discomfort and arousal would
contribute to elevations in ICP that in turn would be
counteracted with increased sedative/analgesic use. This
mechanism, unique for neurointensive patients, in particu-
lar those with aSAH, might explain the increasing use of
sedatives/analgesics during the days prior to PT, in contrast
to a general ICU population [22].
Our study suggests that PT is particularly well indicated
in the aSAH population because it allows ICP and ABP
control with much smaller amounts of sedative/analgesic
drugs and opioids. This makes it difficult to detect severe
vasospasm, and clinical signs are easier to monitor if the
patient is awake. Documented serious vasospasm was
treated with deep sedation and elevation of the CPP thresh-
old in excess of 90 mmHg. No PTs were performed during
the phase of serious cerebral vasospasm or other neuro-
logical instabilities. After PT, we observed a concomitant
increase in CPP that was probably caused by the rapid
decrease in sedatives/analgesics, given that there were no
changes in the prescribed target CPP values. Although theincrease in CPP was statistically significant, it was probably
not of clinical impact.
Reduced sedation was associated with changing the ven-
tilator mode; however, a retrospective analysis does not
allow conclusions regarding this synergy. The fact that a
significant number of patients went from controlled mode
to spontaneous ventilation after PT was likely due to the
greatly reduced opioid doses.
Population-related factors
The present 3-month mortality rate of 25% was below
the average in our general ICU population (30%) [2].
Mortality was also low compared with previously pub-
lished data [23,24], particularly considering our high
fraction of patients who presented with Hunt & Hess
grades 4 and 5 (“poor grade”). Mortality in this subgroup
is reportedly as high as 75% [13,14]. The observation of
a significantly poorer clinical grade in the patient popu-
lation that underwent PT is expected, because patients
with an anticipated long course of disease were more
likely to be selected for PT. Aneurysmal SAH is more
common in women [25,26]; correspondingly, more
women underwent PT. The reason for a higher fraction
of women being in a poorer clinical state prior to
aneurysm repair is not obvious from the available data,
but may be related to age, pre-existing co-morbidity, de-
lays in seeking medical attention, larger hemorrhages, or
possibly more problems with acute hydrocephalus.
Limitations of the study
The available observational data cannot answer the ques-
tion of whether tracheotomy improved outcome or had an
effect on the duration of hospitalization in this patient
population. Although retrospective analyses may document
associations and generate hypotheses, they cannot prove
causation. A randomized trial with multifactorial analysis is
necessary to investigate these aspects of PT.
Regrettably, the ICU did not register sedation and agita-
tion scores for the patients during the entire study period.
This limits our ability to interpret our findings regarding
drug consumption. Likewise, GCS could not be retrieved
for all days before and after PT in all patients.
Conclusions
Percutaneous tracheotomy in aSAH patients is a swift
procedure with low risk that is associated with a signifi-
cant decline in the consumption of sedative/analgesic
and vasoactive drugs while clinical surveillance parame-
ters remain stable or improve.
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